Patient-Derived Xenografts (PDX) are the gold standard in oncology drug development models. They provide early disease-relevant data to reduce the risk of candidate late-stage failure and bring your drug to the market faster.
This webinar will give you insights on how in silico, in vitro, and in vivo, PDX tools can optimize your preclinical phase, thanks to translationally relevant tumor biology models. We discuss:
- A variety of in vitro platforms based on PDX tissue for screening or mechanistic studies
- PDX models as an in vivo platform for your immune-oncology, cell therapy, and biomarker development
- In silico tools that can confirm robustness and predictivity of in vivo testing results
Watch and gain insights to improve your future efficacy and get closer to developing a breakthrough drug.
Webinar Presenter
Julia Schueler, DVM, PhD
Therapeutic Area Lead
Charles River
Offered Free by: CG Life
See All Resources from: CG Life
